HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH RSS TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Bajén, M T. Articles by Ramón García, J. Search for Related Content PubMed PubMed Citation Articles by Bajén, M T. Articles by Ramón García, J.

Effect of a Diagnostic Dose of 185 MBq ¹³¹I on Postsurgical Thyroid Remnants

Medicina Nuclear, Center de Tecnologia Diagnòstica, Tarrasa, Spain

Stunning of thyroid remnants after diagnostic scanning with ¹³¹I may limit ¹³¹I therapy. The follow-up scans and serum thyroglobulin levels of such patients have been studied. Methods: Three-hundred seventy-eight patients who underwent thyroidectomy for differentiated thyroid carcinoma were studied. Diagnostic scans were obtained with 185 MBq ¹³¹I; 7.2 wk afterward, the patients received 489 ablative treatments with 4 GBq ¹³¹I. A total of 1575 scans were obtained (pre- and posttreatment scans and 615 follow-up scans). The evolution of serum thyroglobulin levels was determined. Results: In all patients, the thyroid-stimulating hormone level was more than 30 µIU/mL. Posttherapy scans showed less uptake than did diagnostic scans or even showed negative findings in 99 patients (21%). In these patients, the mean time between diagnostic scanning and therapy was 7.9 wk. In 61 of these 99 patients (61.6%), follow-up scans have shown negative findings, serum thyroglobulin was less than 3 ng/mL, and antithyroglobulin antibodies were not present. Twenty-three patients (23.2%) have not undergone follow-up scanning yet. In 8 patients (8.1%), follow-up scans showed negative findings but serum thyroglobulin was more than 3 ng/mL. In 7 patients (7.1%), follow-up scans showed less uptake than posttherapy scans, but the findings were not yet negative and thyroglobulin was less than 3 ng/mL. Conclusion: Our data suggest that a stunning effect does not exist for doses of 185 MBq ¹³¹I for diagnostic scans. However, a therapeutic effect may exist.

Key Words: stunning effect • diagnostic dose • ¹³¹I treatment • differentiated thyroid carcinoma

Received Nov. 29, 1999; revision accepted May 16, 2000.

For correspondence or reprints contact: M^a Teresa Bajén, MD, Center de Medicine Diagnòstica, Paris, 83-85 sot. 2^a, 08029 Barcelona, Spain.

This article has been cited by other articles:

				C. Lundh, U. Lindencrona, P. Postgard, T. Carlsson, M. Nilsson, and E. Forssell-Aronsson Radiation-Induced Thyroid Stunning: Differential Effects of 123I, 131I, 99mTc, and 211At on Iodide Transport and NIS mRNA Expression in Cultured Thyroid Cells J. Nucl. Med., July 1, 2009; 50(7): 1161 - 1167. [Abstract] [Full Text] [PDF]

				E. B. Silberstein Comparison of Outcomes After 123I Versus 131I Preablation Imaging Before Radioiodine Ablation in Differentiated Thyroid Carcinoma J. Nucl. Med., July 1, 2007; 48(7): 1043 - 1046. [Abstract] [Full Text] [PDF]

				C. Lundh, M. M. Norden, M. Nilsson, and E. Forssell-Aronsson Reduced Iodide Transport (Stunning) and DNA Synthesis in Thyrocytes Exposed to Low Absorbed Doses from 131I In Vitro J. Nucl. Med., March 1, 2007; 48(3): 481 - 486. [Abstract] [Full Text] [PDF]

				J. C. Sisson, A. M. Avram, S. A. Lawson, P. G. Gauger, and G. M. Doherty The So-Called Stunning of Thyroid Tissue J. Nucl. Med., September 1, 2006; 47(9): 1406 - 1412. [Abstract] [Full Text] [PDF]

				B Jarzab, D Handkiewicz-Junak, and J Wloch Juvenile differentiated thyroid carcinoma and the role of radioiodine in its treatment: a qualitative review Endocr. Relat. Cancer, December 1, 2005; 12(4): 773 - 803. [Abstract] [Full Text] [PDF]

				A F Leger, M Pellan, F Dagousset, A Chevalier, I Keller, and J Clerc A case of stunning of lung and bone metastases of papillary thyroid cancer after a therapeutic dose (3.7 GBq) of 131I and review of the literature: implications for sequential treatments Br. J. Radiol., May 1, 2005; 78(929): 428 - 432. [Abstract] [Full Text] [PDF]

				S. K. Gerard and H. Q. Dam Stunning with 131I Diagnostic Whole-Body Imaging of Patients with Thyroid Cancer * Dr Dam responds: Radiology, March 1, 2005; 234(3): 972 - 974. [Full Text] [PDF]

				H. Q. Dam, S. M. Kim, H. C. Lin, and C. M. Intenzo 131I Therapeutic Efficacy Is Not Influenced by Stunning after Diagnostic Whole-Body Scanning Radiology, August 1, 2004; 232(2): 527 - 533. [Abstract] [Full Text] [PDF]

				P. Postgard, J. Himmelman, U. Lindencrona, N. Bhogal, D. Wiberg, G. Berg, S. Jansson, E. Nystrom, E. Forssell-Aronsson, and M. Nilsson Stunning of Iodide Transport by 131I Irradiation in Cultured Thyroid Epithelial Cells J. Nucl. Med., June 1, 2002; 43(6): 828 - 834. [Abstract] [Full Text] [PDF]

				J. Hermanska, M. Karny, J. Zimak, L. Jirsa, M. Samal, and P. Vlcek Improved Prediction of Therapeutic Absorbed Doses of Radioiodine in the Treatment of Thyroid Carcinoma J. Nucl. Med., July 1, 2001; 42(7): 1084 - 1090. [Abstract] [Full Text] [PDF]